Drug Approval | April 26, 2022
ZyCoV-D two-dose vaccine receives Emergency Use Approval from DCGI
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
Key findings underscore the need for better control of glycemia, blood pressure and lipid parameters to prevent diabetes-related complications
Machine learning approach to systems biology combined with ligand discovery platform
SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
Antibiotics mixed in wastewater often get disposed of into the water bodies resulting in wider antimicrobial resistance cases
The tablet donations provided for the treatment of more than 600 million schoolchildren in affected countries in sub-Saharan Africa since 2007
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response
These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
Subscribe To Our Newsletter & Stay Updated
